Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 28 Nov 2018 |
| Orion Corporation: Managers' transactions - Mikael Silvennoinen | 27 Nov 2018 |
| Orion Corporation: Managers' transactions - Leevi Westerlund | 30 Oct 2018 |
| Orion Corporation: Managers' transactions - Konsta Westerlund | 30 Oct 2018 |
| Orion Corporation: Managers' transactions - Riikka Westerlund | 30 Oct 2018 |